Form 4: Entera Bio Director Receives Equity Compensation

Entera Bio Ltd. Director Gerald M. Ostrov received 28,721 ordinary shares and 33,505 stock options as compensation for services.

Summary

• Gerald M. Ostrov, a Director of Entera Bio Ltd. (ENTX), acquired 28,721 ordinary shares on January 1, 2026.
• These shares were awarded by the Board of Directors in lieu of cash fees for services rendered as a director during the 2025 fiscal year.
• Mr. Ostrov also acquired 33,505 stock options on January 1, 2026, with an exercise price of $1.94 per share.
• These options represent the Board's annual grant to directors and will vest ratably on a quarterly basis over a one-year period, commencing January 1, 2026.
• The stock options have an expiration date of January 1, 2036.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates alignment of director interests with shareholders through equity compensation, which is a standard and generally favorable governance practice. No significant negative financial implications are immediately apparent.

Positives

• The award of shares and options to a director aligns management's interests with those of shareholders, encouraging long-term value creation.
• Utilizing equity compensation in lieu of cash fees can help conserve the company's cash reserves.

Negatives

• The issuance of new shares and options could result in minor dilution for existing shareholders.

Risks

• The value of the equity compensation (shares and options) is subject to market fluctuations, which could impact the director's compensation value.
• Future stock price performance will determine the ultimate value realized from the stock options.

Future Outlook

The stock options will vest ratably on a quarterly basis over a one-year period starting January 1, 2026, indicating a future schedule for the director's equity accumulation.

Industry Context

The practice of compensating directors with equity, including shares and stock options, is a common and widely accepted practice across various industries, particularly in biotechnology and growth-oriented companies, to align leadership incentives with shareholder value.

Comparison to Industry Standards

• The use of equity compensation (shares and stock options) for non-executive directors is a standard practice in the biotechnology sector, comparable to compensation structures seen at companies like BioNTech or Moderna, which often use equity to attract and retain talent and align interests.
• The vesting schedule for options over one year is typical for annual director grants, ensuring continued engagement and performance over the short to medium term, similar to practices at many publicly traded pharmaceutical and biotech firms.

Corporate Governance

Related Party Transactions

• The compensation of Director Gerald M. Ostrov with ordinary shares and stock options constitutes a related party transaction, as it involves a director of the company.

Stakeholder Impact

• Shareholders: Minor potential for dilution from the issuance of new shares and options, but also potential for improved alignment of director interests with shareholder value.
• Employees: No direct impact mentioned in this filing.
• Customers: No direct impact mentioned in this filing.
• Suppliers: No direct impact mentioned in this filing.
• Creditors: No direct impact mentioned in this filing.

Next Steps

• The stock options will vest quarterly over the next year, commencing January 1, 2026.

Key Dates

Keywords

Entera Bio, ENTX, Director Compensation, Equity Grant, Stock Options, Ordinary Shares, Insider Transaction, Form 4, Corporate Governance